Products
Sifalimumab Biosimilar Monoclonal Antibody (IFN-α) for Research
Pre-Made Sifalimumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Sifalimumab is a human monoclonal antibody designed for the treatment of SLE, dermatomyositis, and polymyositis. It targets interferon a.
Order Information
| Catalog No. | Package | List Price(In USD) | Discount off | Discount Price |
|---|---|---|---|---|
| GMP-Bios-ab-519-1mg | 1mg | 3090 |
Size： 1mg | 10mg | 100mg
Product Details
| Products Name (INN Index) | Pre-Made Sifalimumab biosimilar, Whole mAb, Anti-IFNA1 Antibody: Anti-IFL/IFN3/leIF DD therapeutic antibody |
| INN Name | Sifalimumab |
| Target | IFNA1 |
| Format | Whole mAb |
| Derivation | Human |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-II |
| Est. Status | Discontinued |
| 100% SI Structure | 4ypg:HL:BA |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2009 |
| Year Recommended | 2010 |
| Companies | Medarex;MedImmune |
| Conditions Approved | na |
| Conditions Active | na |
| Conditions Discontinued | Myositis;Psoriasis;Systemic lupus erythematosus |
| Development Tech | na |
About target - IFNA1
1. Protein Interferon alpha-1/13
2. Gene IFNA1
3. Organism Homo sapiens (Human)
Function
Produced by macrophages, IFN-alpha have antiviral activities. Interferon stimulates the production of two enzymes: a protein kinase and an oligoadenylate synthetase.
Miscellaneous
Interferons alpha-1 and alpha-13 have identical protein sequences.
